New Clinical Trial: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (NCT04931342)

WHY IT MATTERS

This trial offers personalized treatment options for patients with recurrent or persistent rare epithelial ovarian cancers, where standard treatments have failed or stopped working—a situation with very limited options.

Researchers are testing new cancer treatments for people with rare types of ovarian cancer that have come back or didn't go away after initial treatment. The study will test different medicines based on specific genetic markers found in each patient's tumor. About 176 patients will participate, and the trial is being run by Roche, a major pharmaceutical company.

NCT ID: NCT04931342 Status: ACTIVE_NOT_RECRUITING Conditions: Ovarian Cancer Phase: PHASE2 Enrollment: 176 Sponsor: Hoffmann-La Roche Summary: This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.

ASK YOUR DOCTOR

If you have persistent or recurrent rare ovarian, fallopian tube, or peritoneal cancer, ask your oncologist whether you might be eligible for this trial (NCT04931342) and whether biomarker testing of your tumor has been done.